Abstract：Objective To evaluate the 8th edition of AJCC/UICC staging system for stage Ⅲ nasopharyngeal carcinoma (NPC) by the survival analysis. All patients were treated with intensity-modulated radiotherapy (IMRT). Methods Among 1351 treatment-naïve NPC patients who received radiotherapy/chemoradiotherapy in our hospital from December 2008 to October 2014, 742 and 784 cases were classified as clinical stage Ⅲ based on the criteria of the 7th and 8th edition of AJCC/UICC staging systems, respectively. These patients were classified into three subgroups according to the 7th and 8th edition of AJCC/UICC staging systems:T3N0-1 as G1(n=226, n=245), T1-2N2 as G2(n=180, n=187) and T3N2 as G3(n=336, n=352). The 5-year overall survival (OS), progression-free survival (PFS), distant metastasis-free survival (DMFS) and local-regional recurrence-free survival (LRRFS) were analyzed with Kaplan-Meier method. The differences among different groups were evaluated by log-rank test. Results There were 93.6% patients evaluated by the 8th AJCC/UICC staging system remained the same cohort with those by the 7th AJCC/UICC staging system. The 5-year OS, PFS, DMFS and LRRFS of the 8th and 7th staging systems were 84.8% and 85.4%, 76.2% and 77.0%, 80.4% and 81.3%, 89.8% and 90.6%, respectively (all P>0.05). The OS, PFS or DMFS significantly differed among three subgroups classified by the 8th staging system (all P<0.001). In addition, statistical significance was observed between G1 and G2, and between G1 and G3(both P<0.05), whereas no statistical significance was noted between G2 and G3(P=0.183, 0.310, 0.248). Conclusions The distribution features and clinical endpoints of clinical stage Ⅲ defined by the 8th AJCC/UICC staging system are similar to those defined by the 7th AJCC/UICC staging system. The distribution of survival risk significantly differs among different subgroups. N2 plays a major role in assessing the survival risk of patients with stage Ⅲ NPC. In the era of IMRT plus chemotherapy, the effect of local tumors on clinical prognosis has been diminished. The 8th AJCC/UICC staging system remains to be further improved.
Hong Yingji,Li Mei,Yang Zhining et al. Discussion of the 8th edition of AJCC/UICC staging system from the clinical stage Ⅲ nasopharyngeal carcinoma[J]. Chinese Journal of Radiation Oncology, 2020, 29(10): 822-826.
[1] Chua M, Wee J, Hui EP, et al. Nasopharyngeal carcinoma[J]. Lancet, 2016, 387(10022):1012-1024. DOI:10.1016/S0140-6736(15)00055-0. [2] Razak AR, Siu LL, Liu FF, et al. Nasopharyngeal carcinoma:the next challenges[J]. Eur J Cancer, 2010, 46(11):1967-1978. DOI:10.1016/j.ejca.2010.04.004. [3] Marta GN, Silva V, de Andrade CH, et al. Intensity-modulated radiation therapy for head and neck cancer:systematic review and meta-analysis[J]. Radiother Oncol, 2014, 110(1):9-15. DOI:10.1016/j.radonc.2013.11.010. [4] Sun X, Su S, Chen C, et al. Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma:an analysis of survival and treatment toxicities[J]. Radiother Oncol, 2014, 110(3):398-403. DOI:10.1016/j.radonc.2013.10.020. [5] Wu LR, Liu YT, Jiang N, et al. Ten-year survival outcomes for patients with nasopharyngeal carcinoma receiving intensity-modulated radiotherapy:An analysis of 614 patients from a single center[J]. Oral Oncol, 2017, 6(1):26-32. DOI:10.1016/j.oraloncology.2017.03.015. [6] Au KH, Ngan R, Ng A, et al. Treatment outcomes of nasopharyngeal carcinoma in modern era after intensity modulated radiotherapy (IMRT) in Hong Kong:A report of 3328 patients (HKNPCSG 1301 study)[J]. Oral Oncol, 2018, 77(1):16-21. DOI:10.1016/j.oraloncology.2017.12.004. [7] Huang SH, O′Sullivan B. Overview of the 8th edition TNM classification for head and neck Cancer[J]. Curr Treat Options Oncol, 2017, 18(7):40. DOI:10.1007/s11864-017-0484-y. [8] 中国鼻咽癌临床分期工作委员会. 中国鼻咽癌分期2017版(2008鼻咽癌分期修订专家共识)[J]. 中华放射肿瘤学杂志, 2017, 26(10):1119. DOI:10.3760/cma.j.issn.1004-4221.2017.10.002. Chinese Committee for Staging of Nasopharyngeal Carcinoma. The 2017 edition for staging of nasopharyngeal carcinoma in China (The Chinese 2008 expert consensus on staging revision of nasopharyngeal carcinoma)[J]. Chin J Radiat Oncol, 2017, 26(10):1119. DOI:10.3760/cma.j.issn.1004-4221.2017.10.002. [9] Ouyang PY, Xiao Y, You KY, et al. Validation and comparison of the 7th and 8th edition of AJCC staging systems for non-metastatic nasopharyngeal carcinoma, and proposed staging systems from Hong Kong, Guangzhou, and Guangxi[J]. Oral Oncol, 2017, 72(1):65-72. DOI:10.1016/j.oraloncology.2017.07.011. [10] Kang M, Zhou P, Li G, et al. Validation of the 8th edition of the UICC/AJCC staging system for nasopharyngeal carcinoma treated with intensity-modulated radiotherapy[J]. Oncotarget, 2017, 8(41):70586-70594. DOI:10.18632/oncotarget.19829. [11] Tang LL, Chen YP, Mao YP, et al. Validation of the 8th edition of the UICC/AJCC staging system for nasopharyngeal carcinoma from endemic areas in the intensity-modulated radiotherapy era[J]. J Natl Compr Canc Netw, 2017, 15(7):913-919. DOI:10.6004/jnccn.2017.0121. [12] Ng WT, Lee MC, Chang AT, et al. The impact of dosimetric inadequacy on treatment outcome of nasopharyngeal carcinoma with IMRT[J]. Oral Oncol, 2014, 50(5):506-512. DOI:10.1016/j.oraloncology.2014.01.017. [13] Groome PA, Schulze KM, Mackillop WJ, et al. A comparison of published head and neck stage groupings in carcinomas of the tonsillar region[J]. Cancer, 2001, 92(6):1484-1494. DOI:10.1002/1097-0142(20010915)92:6<1484::aid-cncr1473>3.0.co;2-w. [14] 高劲,陈晨,陶亚岚,等. IMRT时代鼻咽癌临床分期的降期新建议研究[J]. 中华放射肿瘤学杂志, 2017, 26(6):614. DOI:10.3760/cma.j.issn.1004-4221.2017.06.002. Gao J, Chen C, Tao YL, et al. New suggestion for clinical downstaging of nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy[J]. Chin J Radiat Oncol, 2017, 26(6):614. DOI:10.3760/cma.j.issn.1004-4221.2017.06.002. [15] Han L, Lin SJ, Pan JJ, et al. Prognostic factors of 305 nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy[J]. Chin J Cancer, 2010, 29(2):145-150. DOI:10.5732/cjc.009.10332. [16] Su SF, Han F, Zhao C, et al. Long-term outcomes of early-stage nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy alone[J]. Int J Radiat Oncol Biol Phys, 2012, 82(1):327-333. DOI:10.1016/j.ijrobp.2010.09.011. [17] Sun Y, Tang LL, Chen L, et al. Promising treatment outcomes of intensity-modulated radiation therapy for nasopharyngeal carcinoma patients with N0 disease according to the seventh edition of the AJCC staging system[J]. BMC Cancer, 2012, 12(1):68. DOI:10.1186/1471-2407-12-68. [18] Lee A, Ng WT, Chan LK, et al. The strength/weakness of the AJCC/UICC staging system (7th edition) for nasopharyngeal cancer and suggestions for future improvement[J]. Oral Oncol, 2012, 48(10):1007-1013. DOI:10.1016/j.oraloncology.2012.03.022. [19] Chen L, Mao YP, Xie FY, et al. The seventh edition of the UICC/AJCC staging system for nasopharyngeal carcinoma is prognostically useful for patients treated with intensity-modulated radiotherapy from an endemic area in China[J]. Radiother Oncol, 2012, 104(3):331-337. DOI:10.1016/j.radonc.2011.10.009. [20] Zong J, Lin S, Lin J, et al. Impact of intensity-modulated radiotherapy on nasopharyngeal carcinoma:validation of the 7th edition AJCC staging system[J]. Oral Oncol, 2015, 51(3):254-259. DOI:10.1016/j.oraloncology.2014.10.012.
2020, Vol. 29 
